FDA Approves Immunotherapy That May Allow Certain Patients with Rectal Cancer to Avoid Chemotherapy, Radiation and Surgery
- FDA: 37 events in the last 90 days
- Previous: 2 days earlier · RFK Jr. proposes FDA look the other way on unproven peptides, report says
What happened
The U.S. Food and Drug Administration today granted accelerated approval for a new use of the immunotherapy Jemperli (dostarlimab-gxly) that may allow some patients with locally advanced rectal cancer to avoid common treatments that can have a lasting impact on their daily life.
Summary assembled by rule from the sources below